Horizon Therapeutics (HPTX) & Its Peers Financial Survey

Horizon Therapeutics (NASDAQ: HPTX) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Horizon Therapeutics to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Horizon Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Horizon Therapeutics Competitors 157 819 1802 61 2.62

As a group, “Biopharmaceuticals” companies have a potential upside of 2.71%. Given Horizon Therapeutics’ rivals higher probable upside, analysts clearly believe Horizon Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Horizon Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Horizon Therapeutics Competitors -13,486.12% -54.03% -24.46%

Institutional and Insider Ownership

42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Horizon Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Horizon Therapeutics N/A N/A -1,533.00
Horizon Therapeutics Competitors $584.27 million $101.79 million 87.38

Horizon Therapeutics’ rivals have higher revenue and earnings than Horizon Therapeutics. Horizon Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Horizon Therapeutics rivals beat Horizon Therapeutics on 5 of the 8 factors compared.

Horizon Therapeutics Company Profile

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.